Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207
- 1 February 2006
- journal article
- Published by Wiley in The Prostate
- Vol. 66 (2) , 200-210
Abstract
BACKGROUND Receptors for luteinizing hormone‐releasing hormone (LHRH) on human prostate cancers can be used for targeted chemotherapy with cytotoxic analogs of LHRH, such as AN‐207, which consists of superactive doxorubicin derivative 2‐pyrrolino doxorubicin (AN‐201) linked to carrier [d‐Lys6] LHRH. METHODS The effects of AN‐207 and AN‐201 were investigated in DU‐145 androgen independent and LuCaP‐35 androgen sensitive human prostate cancers xenografted into nude mice. Toxicity was evaluated by survival rates, changes in body weights, and leukocyte counts. LHRH receptors on DU‐145 and LuCaP‐35 tumors were evaluated by radioreceptor assays and RT‐PCR. The effects on apoptosis and cell proliferation were investigated by histology and evaluation of apoptotic oncogenes Bcl‐2 and Bax by Western Blot analysis. RESULTS AN‐207 inhibited growth of DU‐145 tumors significantly by 75% (P < 0.01) and LuCaP‐35 human prostate cancers by 80% (P < 0.01), and was less toxic than AN‐201. Receptors for LHRH were expressed on DU‐145 and LuCaP‐35 tumors. Blockade of LHRH receptors with LHRH agonist Triptorelin nullified the effects of AN‐207. Treatment with AN‐207, but not with AN‐201, decreased Bcl‐2/Bax ratio in DU‐145 tumors and Bcl‐2 in LuCaP‐35 tumors indicating an increase in apoptotic activity. AN‐207, but not AN‐201, decreased cell proliferation in both models. CONCLUSIONS Targeted chemotherapy with AN‐207 could be considered for treatment of advanced prostate cancer.Keywords
This publication has 37 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Chemotherapy targeted to cancers through tumoral hormone receptorsTrends in Endocrinology & Metabolism, 2004
- LuCaP 35: A new model of prostate cancer progression to androgen independenceThe Prostate, 2003
- A history of prostate cancer treatmentNature Reviews Cancer, 2002
- Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinomaCancer, 2002
- Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapyDrugs of the Future, 2002
- Hypothalamic Hormones and CancerFrontiers in Neuroendocrinology, 2001
- Gonadotropin‐releasing hormone receptor expression in the human prostateThe Prostate, 2001
- Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitroHuman & Experimental Toxicology, 1996
- Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.Proceedings of the National Academy of Sciences, 1996